IMBiologics is a biotechnology company established in August 2020 with the slogan ‘Innovative Medicines based on ImmunoModulatory Biologics'.

Our goal is to invent novel treatment options for autoimmune diseases and cancer, utilizing antibodies to modulate the immune system through innovative mechanisms of action. We have initiated the journey with a 4 Billion KRW seed fund in 2020 to enable the development of proprietary antibody platform technology as well as the in-house R&D of novel bispecific antibody assets. IMB successfully raised 13 Billion KRW in Series A financing in August 2021 and 20 Billion KRW in Series B funding in July 2023, and we are fully committed to accelerating the antibody R&D processes. We are conducting a clinical development of IMB-101 in USA and developing the innovative immune oncology pipelines with novel MoA.

Our vision is to develop Innovative Medicines based on ImmunoModulatory Biologics in areas of greatest unmet medical needs to become a global biotechnology company that benefits the world.